Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in the United States (US), European Union (EU), and other countries as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) [1, 2]. This evidence concerns the gene SLC5A2 and diabetes mellitus.